Press "Enter" to skip to content

USFDA inspection at Indore facility ends with zero observations: Cipla

"We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019," the company said in a BSE filing.

Original source:

Also Read:   PharmEasy in talks with SoftBank to raise $100M: report